Saturday 17 October 2026
Export CRDL’s income statement to Excel — free account
Cardiol Therapeutics Inc.
CRDL Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS grew 42.9%, free cash flow grew 10.6% and total debt fell 38.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.10
0.05
−4.35%
Follow CRDL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (171.13%) | (159.27%) | (156.96%) | (375.38%) |
+8 more TTM periods Free account |
|
| (124.40%) | (117.20%) | (120.54%) | (246.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(127.30%) | (134.49%) | (188.25%) | (390.50%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.15) | (0.16) | (0.20) | (0.21) | |
Free Cash Flow |
(17.24) | (17.61) | (17.09) | (17.56) | |
Capital Expenditures |
(0.04) | (0.04) | (0.02) | (0.02) | |
| Other line items | |||||
Cash ROIC |
(47.58%) | (46.51%) | (60.64%) | (113.69%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.74 | 0.71 | 0.64 | |
Depreciation/Fixed assets |
0.68 | 0.74 | 0.86 | 0.88 | |
Capex/Depreciation |
(0.64) | (0.58) | (0.24) | (0.22) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.15) | (0.16) | (0.20) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates